• To global navigation
  • To contents

Mitsubishi Tanabe Pharma

  • HOME
  • JAPANESE TOP
  • Site Map
  • Contact Us

Mitsubishi Chemical Holdings Group

Print

  • Corporate Information
    • Message From The Management
    • Philosophy and Vision,Corporate Behavior Charter
    • Quality Policy
    • Compliance
    • Medium-Term Management Plan
    • Corporate Data
    • Management
    • Organization Chart
    • Network
    • Group Companies
    • Brand Mark
    • Corporate History
    • CSR Report
  • Research&Development
    • Developing Innovative New Drugs
    • R&D Pipeline
    • Clinical Trial Information
    • Research Reagent
  • Investor Relations
    • IR Top
    • Shareholder's Meeting
    • Financial Results
    • Financial Data
    • IR Meeting
    • Annual Report
    • IR Library
    • FAQ
    • IR Calendar
    • IR Inquiries
    • Cautionary Note
  • News Release
    • News Release
    • Topics

HOME>News Release>Mitsubishi Pharma Corporation

News Release : Mitsubishi Pharma Corporation 2004

  • Mitsubishi Tanabe Pharma
  • Former TANABE SEIYAKU
  • Former Mitsubishi Pharma
  • 2007
  • 2006
  • 2005
  • 2004
  • 2003
  • 2002
  • 2001

2004

12/24
Drug-manufacturing plants to be spun off PDF
12/24
Spin-off of packaging and distribution functions through business transfer PDF
11/4
Mitsubishi Pharma and Takeda to Terminate License Agreement on an Agent for Cardiac Diseases
9/15
Notice of revised business result forecast (consolidated and non-consolidated) PDF
7/27
New packaging and distribution company to be established
7/5
New launch of airway secretion cell normalizing agents:SPELEAR solution 8% and Cleanal ORAL SOLUTION 8%
4/27
Reallocation of representative directors PDF
4/20
Organizational Integration of Mitsubishi Pharma Chinese Operations
4/6
Acquisition of Shares of Green Cross Guangzhou Pharmaceutical Co., Ltd.
1/27
Outline of total cost reduction projec PDF

News Release

  • News Release
  • Topics
  • Contact Us
  • Terms Of Use
  • Privacy Policy

Top of Page

© Mitsubishi Tanabe Pharma Corporation.